Sobi Completes Acquisition of Arthrosi Therapeutics for Up to $1.5 Billion

Sobi Acquires CTI BioPharma Corp.

June 26, 2023

Biotechnology

Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.

Novartis Acquires Anthos Therapeutics for Up to $3.1B

February 11, 2025

Pharmaceuticals

Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Bristol Myers Squibb to Acquire Mirati Therapeutics in $4.8B Cash-and-CVR Deal

October 13, 2023

Pharmaceuticals

Bristol Myers Squibb has entered into a definitive merger agreement to acquire Mirati Therapeutics for $58 per share in cash, valuing the transaction at $4.8 billion in equity value. The deal also includes a non-tradeable contingent value right (CVR) that could provide up to an additional $1 billion of value tied to regulatory acceptance of an NDA for Mirati’s MRTX1719.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.